These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 10318772

  • 1. Cyclic GMP phosphodiesterase-5: target of sildenafil.
    Corbin JD, Francis SH.
    J Biol Chem; 1999 May 14; 274(20):13729-32. PubMed ID: 10318772
    [No Abstract] [Full Text] [Related]

  • 2. Phosphodiesterase 5A as a target in cardiac disease.
    Doggrell SA.
    Expert Opin Ther Targets; 2005 Oct 14; 9(5):1097-100. PubMed ID: 16185160
    [No Abstract] [Full Text] [Related]

  • 3. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal.
    Atz AM, Wessel DL.
    Anesthesiology; 1999 Jul 14; 91(1):307-10. PubMed ID: 10422958
    [No Abstract] [Full Text] [Related]

  • 4. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage.
    Rodríguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Espinoza F, Pons H, Vaziri ND.
    Kidney Int; 2005 Nov 14; 68(5):2131-42. PubMed ID: 16221212
    [Abstract] [Full Text] [Related]

  • 5. Sildenafil (Viagra) and ophthalmology.
    Marmor MF.
    Arch Ophthalmol; 1999 Apr 14; 117(4):518-9. PubMed ID: 10206581
    [No Abstract] [Full Text] [Related]

  • 6. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery.
    Pauvert O, Lugnier C, Keravis T, Marthan R, Rousseau E, Savineau JP.
    Br J Pharmacol; 2003 Jun 14; 139(3):513-22. PubMed ID: 12788811
    [Abstract] [Full Text] [Related]

  • 7. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
    Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA.
    Nat Med; 2005 Feb 14; 11(2):214-22. PubMed ID: 15665834
    [Abstract] [Full Text] [Related]

  • 8. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise.
    Traverse JH, Chen YJ, Du R, Bache RJ.
    Circulation; 2000 Dec 12; 102(24):2997-3002. PubMed ID: 11113052
    [Abstract] [Full Text] [Related]

  • 9. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.
    Hirose R, Okumura H, Yoshimatsu A, Irie J, Onoda Y, Nomoto Y, Takai H, Ohno T, Ichimura M.
    Eur J Pharmacol; 2001 Nov 09; 431(1):17-24. PubMed ID: 11716838
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular data on sildenafil citrate: introduction.
    Zusman RM.
    Am J Cardiol; 1999 Mar 04; 83(5A):1C-2C. PubMed ID: 10078536
    [No Abstract] [Full Text] [Related]

  • 11. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
    Manganiello V.
    Mol Pharmacol; 2003 Jun 04; 63(6):1209-11. PubMed ID: 12761329
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sildenafil does not influence autonomic neurocardiac control assessed by standard measurements of heart rate variability.
    Agelink MW, Ullrich H, Brockmeyer NH.
    Circulation; 2001 Dec 11; 104(24):E145. PubMed ID: 11739321
    [No Abstract] [Full Text] [Related]

  • 14. Acute priapism associated with the use of sildenafil in a patient with sickle cell trait.
    Kassim AA, Fabry ME, Nagel RL.
    Blood; 2000 Mar 01; 95(5):1878-9. PubMed ID: 10744389
    [No Abstract] [Full Text] [Related]

  • 15. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells.
    Moreland RB, Goldstein I, Traish A.
    Life Sci; 1998 Mar 01; 62(20):PL 309-18. PubMed ID: 9600334
    [Abstract] [Full Text] [Related]

  • 16. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Rotella DP, Sun Z, Zhu Y, Krupinski J, Pongrac R, Seliger L, Normandin D, Macor JE.
    J Med Chem; 2000 Apr 06; 43(7):1257-63. PubMed ID: 10753463
    [Abstract] [Full Text] [Related]

  • 17. Should phosphodiesterase 5 selective inhibitors be used for uterine relaxation?
    Méhats C, Schmitz T, Breuiller-Fouché M, Leroy MJ, Cabrol D.
    Am J Obstet Gynecol; 2006 Jul 06; 195(1):184-5. PubMed ID: 16813753
    [Abstract] [Full Text] [Related]

  • 18. Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure.
    Chen Y, Traverse JH, Hou M, Li Y, Du R, Bache RJ.
    Am J Physiol Heart Circ Physiol; 2003 May 06; 284(5):H1513-20. PubMed ID: 12679324
    [Abstract] [Full Text] [Related]

  • 19. Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig.
    Kruuse C, Khurana TS, Rybalkin SD, Birk S, Engel U, Edvinsson L, Olesen J.
    Eur J Pharmacol; 2005 Oct 03; 521(1-3):105-14. PubMed ID: 16182282
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
    Turko IV, Ballard SA, Francis SH, Corbin JD.
    Mol Pharmacol; 1999 Jul 03; 56(1):124-30. PubMed ID: 10385692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.